Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00484757

Acronym

NARKOREX

Enrollment

Unknown

Registered

2007-06-11

Start date

2007-06-30

Completion date

2009-08-31

Last updated

2009-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narcolepsy

Keywords

Narcolepsy, Orexines, sleep, cognition, cytokines

Brief summary

15 patients with narcolepsy and 15 healthy controls will be included in the study. According to a randomized, double-blind protocol they will receive intranasally at night first Orexine A and approximately two weeks later placebo or vice versa. Thereafter sleep will be recorded, the cytokine-system and neurocognition characterized.

Interventions

DRUGOrexine A

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Narcolepsy * Age \>18 * Informed consent * GERMAN fluently spoken

Exclusion criteria

* Additional severe psychiatric or somatic disorders * Pregnancy or nursing * Anemia (Hb\<10g/dl)

Design outcomes

Primary

Measure	Time frame
Effect of orexine A on sleep, neurocognition and immune-system	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026